Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia - 18/02/12
, Judy H. Borovicka, MD a, Alfred Rademaker, PhD b, Dennis P. West, PhD a, Maria Colavincenzo, MD a, c, Heather Wickless, MD a, c
Correspondence to: Ann Cameron Haley, BA, Department of Dermatology, Northwestern University, 676 N St Clair, Suite 1600, Chicago, IL 60611.Abstract |
Background |
Hair loss may significantly impact an individual’s self-image, and studies indicate that patients with both clinically apparent and clinically imperceptible hair loss may have significantly decreased quality of life (QoL). Moreover, clinical severity of hair loss does not necessarily predict impact on QoL.
Objective |
The aim of this study was to assess QoL in patients (n = 104) with alopecia areata, telogen effluvium, and androgenic alopecia, and to compare QoL with hair loss severity (HLS) as independently rated by both patient and dermatologist.
Methods |
Questionnaires and clinical assessment tools were used to assess HLS, and QoL was measured by completion of Skindex-16.
Results |
Overall, patients rated their hair loss as more severe than the dermatologist, and the patient’s HLS rating more strongly correlated with QoL than the dermatologist’s rating. Clinical assessment of HLS did not reliably predict the patient’s QoL, nor did it predict the patient’s perception of HLS.
Limitations |
A convenience sample was recruited from a referral clinic and Skindex-16 has not been validated for use in women’s alopecia disorders.
Conclusion |
These findings indicate dermatologists should address these psychosocial and QoL issues when treating patients with alopecia.
Il testo completo di questo articolo è disponibile in PDF.Key words : alopecia, alopecia areata, androgenic alopecia, quality of life, Skindex-16, telogen effluvium
Abbreviations used : AA, AGA, HLS, QoL, SALT, TE
Mappa
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
|
| Reprints not available from the authors. |
Vol 66 - N° 3
P. e97-e102 - marzo 2012 Ritorno al numero
Articolo precedente
- Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib
- Thomas M. Rünger, Silvano Adami, Claude-Laurent Benhamou, Edward Czerwiński, Jordi Farrerons, David L. Kendler, Linda Mindeholm, Giuseppe Realdi, Christian Roux, Vanessa Smith
- Benchmarking US Department of Veterans Affairs dermatologic services: Results from a national survey
- L. Kendall Krause, Leilani Townsend, Michael L. Orser, Jennifer Mulhausen, Jodi Duke, Weston T. Waxweiler, Robert P. Dellavalle
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?